Integration of Local Therapy with Systemic Treatment in Oligometastatic Disease

ESMO-ESTRO-ESSO Joint Symposium

Introduction

Christoph C. Zielinski
Comprehensive Cancer Center
Medical Univ. Vienna – General Hospital
Vienna, Austria
Disclosure slide

- I have no COI to declare
Clinical Presentation of Malignant Disorders

- Local Malignant Growth
- Oligometastatic Disease
- Plurimetastatic Disease

Definition of Oligometastatic Disease

1-3 or 1-5 Metastases

Synchronous
Metachronous
Concept: Long-Term Survival after Ablation of Oligometastatic Disease

Hazard: Oligometastatic Disease as Tip of the Iceberg

Belinda E. Kiely et al., J Clin Oncol 10.1200/JCO.2010.32.9086
The Oligometastatic Disease Paradigm

„Patients with Malignancy and a Small Number of Metastases if Treated Aggressively by Local Interventions (Surgery, Stereotaxy, etc) Might Achieve Long-Term Survival.“
Overall Survival from First Pulmonary Metastasectomy in Soft Tissue Sarcoma. *

- S. Schur et al., Eur J Cancer 2014 Jul 2. pii: S0959-8049(14)00659-5. doi: 10.1016/j.ejca.2014.05.009
Treatment of Oligometastatic Disease

Few Randomized Trials*

Numerous Non-Randomized Trials and Clinical Observations on Various Patient Sizes with Various Diagnoses**


Lots of Questions in Oligometastatic Disease

- Longitudinal Concepts Including Systemic and Local Therapies (Delay of Systemic Therapy, Abscopal Effect)
- (Supreme or Different?) Efficacy of Local Therapies incl. Surgery, Radiotherapy and Radiofrequency Ablation
- Predictive Factors (micro-RNAs?)
- Divergent Molecular Characteristics?

Randomized Trials:
RTOG 0937 (NSCLC) Trial: PCI +/- Radiotherapy
NSCLC Randomized Phase II Trial: Chemotherapy +/- Local Intervention
PulMiCC Trial: Pulmonary Metastasectomy in mCRC
SABR-COMET Trial: Chemo-/Radiotherapy +/- Stereotactic Ablative Radiotherapy
PRIMULA Study (PI: PierFranco Conte, Padova)